PGR (Progesterone receptor)

This case highlights that isolated adrenal metastasis can occur even after prolonged remission, with hypercalcemia as the sole presenting feature. It emphasizes the need for long-term surveillance in breast cancer survivors and the potential role of surgery in managing isolated adrenal metastases.

This study demonstrates CHCP as a non-thermal (24 °C), non-contact plasma-based IRE platform which induces controlled membrane permeabilization and selective cancer cell death. CHCP offers a translational strategy to eradicate residual tumor cells at the surgical margins, and prevent local recurrence, positioning it as a versatile adjunct in precision surgical oncology.

The discovered LPP phenotype defines a small, high-risk subset warranting external validation. Given the retrospective, single-system design of the study, it is imperative to interpret the discovered phenotype features as hypothesis-generating, rather than as definitive evidence.

Therefore, our study results suggest the significance of genotypic and haplotype analysis of SOCS3 gene polymorphisms and its impact on progression and risk prediction of breast cancer.

GR-driven gene programmes are selectively activated in in vivo models of ERα-positive breast cancer during fasting, and GR knockout hinders the anti-tumour effects of fasting combined with tamoxifen...Additionally, tumours collected after the fasting-mimicking diet showed an inverse correlation of GR activation with proliferation markers, providing clinical confirmation of our observations in animal models. Our results indicate that GR activation has a pivotal role in the ability of fasting to enhance endocrine therapy activity in breast cancer and suggest that corticosteroid administration should be evaluated as an adjuvant to endocrine therapy in this setting.

Based on role of REST in silencing ESR1 expression in cultured myometrial cells, our results support the development of a potential cell culture method to maintain ESR1 expression through REST modulation. Finally, we establish a broad role for REST in epigenetic regulation relevant to leiomyoma pathophysiology.

P2, N=60, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026

A substantial proportion of patients with mBC, particularly those with de novo disease, did not undergo repeat biopsy at progression. These findings reveal disparities in biopsy practices and underscore the need for improved adherence to guideline-based care in community oncology settings.

All 7/7 sequenced tumors harbored the AKT1 c.49G>A variant with no additional oncogenic alterations identified by exome sequencing. This series is the largest series to date documenting the clinicopathologic features of paratesticular tumors, a poorly understood component of the Proteus syndrome phenotype.

P3, N=254, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: Mar 2025 --> Jun 2027

P2, N=6, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Sep 2025 --> Apr 2026

The presence of TLS, especially mature TLS, is associated with favorable clinicopathological features and improved prognosis in patients with primary BC, along with increased CD4+ T cell infiltration, suggesting an important role of TLS in regulating the tumor immune microenvironment. TLS may serve as a potential biomarker for prognosis evaluation and a target for immunomodulatory strategies in BC.